{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:33:07Z","timestamp":1744173187242,"version":"3.40.3"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1007\/s11894-005-0080-3","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T11:51:38Z","timestamp":1180698698000},"page":"485-491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Positioning novel biologic, probiotic, and apheresis therapies for crohn\u2019s disease and ulcerative colitis"],"prefix":"10.1007","volume":"7","author":[{"given":"Laurence J.","family":"Egan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"80_CR1","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1053\/gast.2001.28674","volume":"121","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ, Hanauer SB, Katz S, et al.: Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebocontrolled trial. Gastroenterology 2001, 121:1088\u20131094.","journal-title":"Gastroenterology"},{"issue":"Suppl VI","key":"80_CR2","first-page":"A47","volume":"53","author":"P Rutgeerts","year":"2004","unstructured":"Rutgeerts P, Fedorak RN, Rachmilevich D, et al.: Onercept (recombinant human p55 tumour necrosis factor receptor) treatment in patients with active Crohn\u2019s disease: randomized, placebo-controlled, dose-finding phase II study. Gut 2004, 53(Suppl VI):A47.","journal-title":"Gut"},{"key":"80_CR3","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet 2002, 359:1541\u20131549. A landmark study that established the benefit of long-term therapy with infliximab in luminal Crohn\u2019s disease.","journal-title":"Lancet"},{"key":"80_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group. N Engl J Med 1997, 337:1029\u20131035.","journal-title":"N Engl J Med"},{"key":"80_CR5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1053\/j.gastro.2004.05.010","volume":"127","author":"S Hanauer","year":"2004","unstructured":"Hanauer S, Luk\u00e1s M, MacIntosh D, et al.: A randomized, doubleblind, placebo-controlled trial of the human anti-TNF-a monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn\u2019s disease. Gastroenterology 2004, 127:332.","journal-title":"Gastroenterology"},{"key":"80_CR6","first-page":"A239","volume":"52","author":"P Rutgeerts","year":"2003","unstructured":"Rutgeerts P, Colombel J, Enns R, et al.: Subanalyses from a phase 3 study on the evaluation of natalizumab in active Crohn\u2019s disease therapy-I (ENACT-1). Gut 2003, 52(Suppl):A239.","journal-title":"Gut"},{"key":"80_CR7","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Hanauer SB, Lukas M, et al.: Maintenance of remission over 1 year in patients with active Crohn\u2019s disease treated with adalimumab: results of a blinded placebocontrolled trial. Am J Gastroenterol 2005, in press.","DOI":"10.14309\/00000434-200509001-00843"},{"key":"80_CR8","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, et al.: Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med 1999, 340:1398\u20131405.","journal-title":"N Engl J Med"},{"key":"80_CR9","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, et al.: Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med 2004, 350:876\u2013885. A landmark study that established the benefit of long-term therapy with infliximab in fistulizing Crohn\u2019s disease.","journal-title":"N Engl J Med"},{"key":"80_CR10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/gast.1999.0029900429","volume":"117","author":"E Ricart","year":"1999","unstructured":"Ricart E, Panaccione R, Loftus EV, et al.: Successful management of Crohn\u2019s disease of the ileoanal pouch with infliximab. Gastroenterology 1999, 117:429\u2013432.","journal-title":"Gastroenterology"},{"key":"80_CR11","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1111\/j.1572-0241.2003.07675.x","volume":"98","author":"JF Colombel","year":"2003","unstructured":"Colombel JF, Ricart E, Loftus EV Jr, et al.: Management of Crohn\u2019s disease of the ileoanal pouch with infliximab. Am J Gastroenterol 2003, 98:2239\u20132244.","journal-title":"Am J Gastroenterol"},{"key":"80_CR12","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P, et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 52:582\u2013591.","journal-title":"Arthritis Rheum"},{"key":"80_CR13","first-page":"A26","volume":"128","author":"T Brooklyn","year":"2005","unstructured":"Brooklyn T, Shetty A, Bowden J, et al.: Infliximab for the treatment of pyoderma gangrenosum: a randomised, doubleblind placebo-controlled trial. Gastroenterology 2005, 128:A26.","journal-title":"Gastroenterology"},{"key":"80_CR14","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1053\/gast.2001.24042","volume":"120","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ, Feagan BG, Hanauer SB, et al.: An engineered human antibody to TNF (CDP571) for active Crohn\u2019s disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001, 120:1330\u20131338.","journal-title":"Gastroenterology"},{"key":"80_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1365-2036.2005.02336.x","volume":"21","author":"BG Feagan","year":"2005","unstructured":"Feagan BG, Sandborn WJ, Baker JP, et al.: A randomized, doubleblind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn\u2019s disease. Aliment Pharmacol Ther 2005, 21:373\u2013384.","journal-title":"Aliment Pharmacol Ther"},{"key":"80_CR16","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1136\/gut.2003.035253","volume":"53","author":"WJ Sandborn","year":"2004","unstructured":"Sandborn WJ, Feagan BG, Radford-Smith G, et al.: CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn\u2019s disease: a randomised, double blind, placebo controlled trial. Gut 2004, 53:1485\u20131493.","journal-title":"Gut"},{"key":"80_CR17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0140-6736(97)80083-9","volume":"349","author":"WA Stack","year":"1997","unstructured":"Stack WA, Mann SD, Roy AJ, et al.: Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn\u2019s disease. Lancet 1997, 349:521\u2013524.","journal-title":"Lancet"},{"key":"80_CR18","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","volume":"129","author":"S Schreiber","year":"2005","unstructured":"Schreiber S, Rutgeerts P, Fedorak RN, et al.: A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn\u2019s disease. Gastroenterology 2005, 129:807\u2013818.","journal-title":"Gastroenterology"},{"key":"80_CR19","doi-asserted-by":"publisher","first-page":"A104","DOI":"10.1053\/j.gastro.2005.02.021","volume":"128","author":"WJ Sandborn","year":"2005","unstructured":"Sandborn WJ, Rachmilewitz D, Hanauer SB, et al.: Infliximab induction and maintenance therapy for ulcerative colitis: the ACT2 trial. Gastroenterology 2005, 128:A104-A105.","journal-title":"Gastroenterology"},{"key":"80_CR20","doi-asserted-by":"publisher","first-page":"A105","DOI":"10.1053\/j.gastro.2005.01.010","volume":"128","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Feagan BG, Olson A, et al.: A randomized placebocontrolled trial of infliximab therapy for active ulcerative colitis: ACT 1 trial. Gastroenterology 2005, 128:A105.","journal-title":"Gastroenterology"},{"key":"80_CR21","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098\u20131104. This paper established the potential of in fliximab to cause reactivation of latent tuberculosis, a very serious adverse effect of this agent.","journal-title":"N Engl J Med"},{"key":"80_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","volume":"126","author":"JF Colombel","year":"2004","unstructured":"Colombel JF, Loftus EV Jr, Tremaine WJ, et al.: The safety profile of infliximab in patients with Crohn\u2019s disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004, 126:19\u201331.","journal-title":"Gastroenterology"},{"key":"80_CR23","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/00054725-200409000-00025","volume":"10","author":"FS Velayos","year":"2004","unstructured":"Velayos FS, Sandborn WJ: Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn\u2019s disease. Inflamm Bowel Dis 2004, 10:657\u2013660.","journal-title":"Inflamm Bowel Dis"},{"key":"80_CR24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/00054725-200205000-00005","volume":"8","author":"DL Riegert-Johnson","year":"2002","unstructured":"Riegert-Johnson DL, Godfrey JA, Myers JL, et al.: Delayed hypersensitivity reaction and acute respiratory distress syndrome following in fliximab infusion. Inflamm Bowel Dis 2002, 8:186\u2013191.","journal-title":"Inflamm Bowel Dis"},{"key":"80_CR25","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","volume":"138","author":"HJ Kwon","year":"2003","unstructured":"Kwon HJ, Cote TR, Cuffe MS, et al.: Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003, 138:807\u2013811.","journal-title":"Ann Intern Med"},{"key":"80_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/00054725-200401000-00004","volume":"10","author":"CW Thomas Jr","year":"2004","unstructured":"Thomas CW Jr, Weinshenker BG, Sandborn WJ: Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn\u2019s disease. Inflamm Bowel Dis 2004, 10:28\u201331.","journal-title":"Inflamm Bowel Dis"},{"key":"80_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0016-5085(03)00701-7","volume":"125","author":"S Vermeire","year":"2003","unstructured":"Vermeire S, Noman M, Van Assche G, et al.: Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn\u2019s disease: a prospective cohort study. Gastroenterology 2003, 125:32\u201339.","journal-title":"Gastroenterology"},{"key":"80_CR28","unstructured":"Prescribing information for Humira (adalimumab). Package insert;. Abbot Park, IL: Abbott Labs; 2004."},{"key":"80_CR29","doi-asserted-by":"publisher","first-page":"A61","DOI":"10.1016\/S0016-5085(03)80301-3","volume":"124","author":"S Schreiber","year":"2003","unstructured":"Schreiber S, Rutgeerts P, Fedorak RN, et al.: CDP870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn\u2019s disease. Gastroenterology 2003, 124:A61.","journal-title":"Gastroenterology"},{"key":"80_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1136\/gut.2004.045294","volume":"54","author":"J Cosnes","year":"2005","unstructured":"Cosnes J, Nion-Larmurier I, Beaugerie L, et al.: Impact of the increasing use of immunosuppressants in Crohn\u2019s disease on the need for intestinal surgery. Gut 2005, 54:237\u2013241.","journal-title":"Gut"},{"key":"80_CR31","first-page":"3","volume":"125","author":"M Lemann","year":"2003","unstructured":"Lemann M, Colombel JF, Duclos B, et al.: Infliximab in steroid dependent Crohn\u2019s disease patients treated with azathioprine or 6-mercaptopurine: a randomized double-blind placebo controlled trial. Gastroenterology 2003, 125:3.","journal-title":"Gastroenterology"},{"key":"80_CR32","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1053\/j.gastro.2005.05.064","volume":"129","author":"D Hommes","year":"2005","unstructured":"Hommes D, Baert F, Van Assche G, et al.: Management of recent onset Crohn\u2019s disease: a controlled randomized trial comparing step-up and top-down therapy. Gastroenterology 2005, 129:371.","journal-title":"Gastroenterology"},{"key":"80_CR33","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of in fliximab in Crohn\u2019s disease. N Engl J Med 2003, 348:601\u2013608. This important study demonstrated an association between the presence of anti-infliximab antibodies and the loss of efficacy of this agent.","journal-title":"N Engl J Med"},{"key":"80_CR34","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/gast.2003.50182","volume":"124","author":"WJ Sandborn","year":"2003","unstructured":"Sandborn WJ: Preventing antibodies to in fliximab in patients with Crohn\u2019s disease: optimize not immunize. Gastroenterology 2003, 124:1140\u20131145.","journal-title":"Gastroenterology"},{"key":"80_CR35","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1053\/gast.2003.50145","volume":"124","author":"RJ Farrell","year":"2003","unstructured":"Farrell RJ, Alsahli M, Jeen YT, et al.: Intravenous hydrocortisone premedication reduces antibodies to in fliximab in Crohn\u2019s disease: a randomized controlled trial. Gastroenterology 2003, 124:917\u2013924.","journal-title":"Gastroenterology"},{"key":"80_CR36","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","volume":"2","author":"SB Hanauer","year":"2004","unstructured":"Hanauer SB, Wagner CL, Bala M, et al.: Incidence and importance of antibody responses to in fliximab after maintenance or episodic treatment in Crohn\u2019s disease. Clin Gastroenterol Hepatol 2004, 2:542\u2013553.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"80_CR37","doi-asserted-by":"publisher","first-page":"S255","DOI":"10.1111\/j.1572-0241.2004.40462.x","volume":"99","author":"W Sandborn","year":"2004","unstructured":"Sandborn W, Colombel JF, Enns R, et al.: Efficacy, safety, and tolerability of natalizumab in maintaining clinical response and remission in Crohn\u2019s disease (ENACT-2). Am J Gastroenterol 2004, 99:S255-S256.","journal-title":"Am J Gastroenterol"},{"key":"80_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa020732","volume":"348","author":"S Ghosh","year":"2003","unstructured":"Ghosh S, Goldin E, Gordon FH, et al.: Natalizumab for active Crohn\u2019s disease. N Engl J Med 2003, 348:24\u201332.","journal-title":"N Engl J Med"},{"key":"80_CR39","unstructured":"Sandborn WJ, Colombel JF, Enns R, et al.: Natalizumab induction and maintenance therapy for Crohn\u2019s disease: the ENACT-1 and ENACT-2 trials. N Engl J Med 2005, in press. Results of the largest clinical trials conducted in inflammatory bowel disease to date have established the short- and long-term benefit of anti-integrin therapy for Crohn\u2019s disease."},{"key":"80_CR40","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"G Van Assche","year":"2005","unstructured":"Van Assche G, Van Ranst M, Sciot R, et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease. N Engl J Med 2005, 353:362\u2013368.","journal-title":"N Engl J Med"},{"key":"80_CR41","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1056\/NEJMoa051782","volume":"353","author":"BK Kleinschmidt-Demasters","year":"2005","unstructured":"Kleinschmidt-Demasters BK, Tyler KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005, 353:369\u2013374.","journal-title":"N Engl J Med"},{"key":"80_CR42","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"A Langer-Gould","year":"2005","unstructured":"Langer-Gould A, Atlas SW, Bollen AW, Pelletier D: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005, 353:375\u2013381.","journal-title":"N Engl J Med"},{"key":"80_CR43","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa042982","volume":"352","author":"BG Feagan","year":"2005","unstructured":"Feagan BG, Greenberg GR, Wild G, et al.: Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005, 352:2499\u20132507. A selective inhibitor of leukocyte trafficking into the gut was found efficacious for ulcerative colitis.","journal-title":"N Engl J Med"},{"key":"80_CR44","doi-asserted-by":"publisher","first-page":"A493","DOI":"10.1053\/j.gastro.2005.03.046","volume":"128","author":"S Targan","year":"2005","unstructured":"Targan S, Salzberg BA, Mayer L, et al.: A phase I-II study: Multiple dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with IV steroids. Gastroenterology 2005, 128:A493.","journal-title":"Gastroenterology"},{"key":"80_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1046\/j.1365-2036.2003.01639.x","volume":"18","author":"TJ Creed","year":"2003","unstructured":"Creed TJ, Norman MR, Probert CS, et al.: Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003, 18:65\u201375.","journal-title":"Aliment Pharmacol Ther"},{"key":"80_CR46","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1572-0241.2003.07239.x","volume":"98","author":"G Van Assche","year":"2003","unstructured":"Van Assche G, Dalle I, Noman M, et al.: A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003, 98:369\u2013376.","journal-title":"Am J Gastroenterol"},{"key":"80_CR47","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1053\/j.gastro.2004.05.011","volume":"127","author":"D Hommes","year":"2004","unstructured":"Hommes D, Mikhajlova T, Stoinov S, et al.: Fontolizumab(HuZAF\n                    TM\n                  ), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn\u2019s disease (CD). Gastroenterology 2004, 127:332.","journal-title":"Gastroenterology"},{"key":"80_CR48","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1053\/j.gastro.2004.01.012","volume":"126","author":"H Ito","year":"2004","unstructured":"Ito H, Takazoe M, Fukuda Y, et al.: A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn\u2019s disease. Gastroenterology 2004, 126:989\u2013996; discussion 947.","journal-title":"Gastroenterology"},{"key":"80_CR49","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1056\/NEJMoa033402","volume":"351","author":"PJ Mannon","year":"2004","unstructured":"Mannon PJ, Fuss IJ, Mayer L, et al.: Anti-interleukin-12 antibody for active Crohn\u2019s disease. N Engl J Med 2004, 351:2069\u20132079. This clinical trial established the therapeutic benefit in Crohn\u2019s disease of selectively inhibiting a central T-helper type I cytokine, IL-12.","journal-title":"N Engl J Med"},{"key":"80_CR50","doi-asserted-by":"publisher","first-page":"G417","DOI":"10.1152\/ajpgi.00421.2004","volume":"288","author":"F Shanahan","year":"2005","unstructured":"Shanahan F: Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I: pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2005, 288:G417\u2013421.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"80_CR51","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1053\/gast.2000.9370","volume":"119","author":"P Gionchetti","year":"2000","unstructured":"Gionchetti P, Rizzello F, Venturi A, et al.: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305\u2013309.","journal-title":"Gastroenterology"},{"key":"80_CR52","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/S0016-5085(03)00171-9","volume":"124","author":"P Gionchetti","year":"2003","unstructured":"Gionchetti P, Rizzello F, Helwig U, et al.: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebocontrolled trial. Gastroenterology 2003, 124:1202\u20131209.","journal-title":"Gastroenterology"},{"key":"80_CR53","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/gut.53.1.108","volume":"53","author":"T Mimura","year":"2004","unstructured":"Mimura T, Rizzello F, Helwig U, et al.: Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004, 53:108\u2013114.","journal-title":"Gut"},{"key":"80_CR54","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1023\/A:1005588911207","volume":"45","author":"M Guslandi","year":"2000","unstructured":"Guslandi M, Mezzi G, Sorghi M, Testoni PA: Saccharomyces boulardii in maintenance treatment of Crohn\u2019s disease. Dig Dis Sci 2000, 45:1462\u20131464.","journal-title":"Dig Dis Sci"},{"key":"80_CR55","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1136\/gut.2003.037747","volume":"53","author":"W Kruis","year":"2004","unstructured":"Kruis W, Fric P, Pokrotnieks J, et al.: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004, 53:1617\u20131623.","journal-title":"Gut"},{"key":"80_CR56","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1046\/j.1365-2036.2003.01465.x","volume":"17","author":"J Kuisma","year":"2003","unstructured":"Kuisma J, Mentula S, Jarvinen H, et al.: Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003, 17:509\u2013515.","journal-title":"Aliment Pharmacol Ther"},{"key":"80_CR57","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(98)06343-0","volume":"354","author":"BJ Rembacken","year":"1999","unstructured":"Rembacken BJ, Snelling AM, Hawkey PM, et al.: Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999, 354:635\u2013639.","journal-title":"Lancet"},{"key":"80_CR58","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1126\/science.289.5483.1352","volume":"289","author":"L Steidler","year":"2000","unstructured":"Steidler L, Hans W, Schotte L, et al.: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000, 289:1352\u20131355.","journal-title":"Science"},{"key":"80_CR59","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/00054725-200405000-00012","volume":"10","author":"M Naganuma","year":"2004","unstructured":"Naganuma M, Funakoshi S, Sakuraba A, et al.: Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 2004, 10:251\u2013257.","journal-title":"Inflamm Bowel Dis"},{"key":"80_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jca.1000","volume":"16","author":"T Shimoyama","year":"2001","unstructured":"Shimoyama T, Sawada K, Hiwatashi N, et al.: Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apheresis 2001, 16:1\u20139.","journal-title":"J Clin Apheresis"},{"key":"80_CR61","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1007\/s00535-004-1465-z","volume":"39","author":"Y Fukuda","year":"2004","unstructured":"Fukuda Y, Matsui T, Suzuki Y, et al.: Adsorptive granulocyte and monocyte apheresis for refractory Crohn\u2019s disease: an open multicenter prospective study. J Gastroenterol 2004, 39:1158\u20131164.","journal-title":"J Gastroenterol"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-005-0080-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-005-0080-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-005-0080-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-005-0080-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:32:54Z","timestamp":1744165974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11894-005-0080-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["80"],"URL":"https:\/\/doi.org\/10.1007\/s11894-005-0080-3","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"type":"print","value":"1522-8037"},{"type":"electronic","value":"1534-312X"}],"subject":[],"published":{"date-parts":[[2005,11]]},"assertion":[{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}